![Lee R. Brettman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lee R. Brettman
Geen lopende functies
Profiel
Lee R.
Brettman was the founder of Dynogen Pharmaceuticals, Inc. founded in 2002, where he held the title of President & Chief Executive Officer.
He was also a Director at Emergent Product Development Seattle from 2002 to 2010.
Dr. Brettman's former jobs include being a Principal at Vertex Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Schering-Plough Research Institute, and R.W.
Johnson Pharmaceutical Research Institute.
He was also an Entrepreneur-in-Residence at Oxford Bioscience Partners and Chief Medical Officer at Alnara Pharmaceuticals, Inc. Dr. Brettman's education history includes an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Baylor College of Medicine.
Eerdere bekende functies van Lee R. Brettman
| Bedrijven | Functie | Einde |
|---|---|---|
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical products | Directeur/Bestuurslid | 28-10-2010 |
Dynogen Pharmaceuticals, Inc.
 Dynogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Oprichter | 01-02-2009 |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Corporate Officer/Principal | 01-01-2004 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Hoofd Techniek/Wetenschap/O&O | 01-01-2001 |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Hoofd Techniek/Wetenschap/O&O | 01-01-1999 |
Opleiding van Lee R. Brettman
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
77
Eerstegraads connecties
11
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 11 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Health Technology |
Dynogen Pharmaceuticals, Inc.
Dynogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical products | Health Technology |
Alnara Pharmaceuticals, Inc.
 Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics for the treatment of metabolic diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Baylor College of Medicine
 Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Health Technology |
R.W. Johnson Pharmaceutical Research Institute |
